Eisai

Profil de la société

Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Description disponible en anglais.

Informations sur la société

Secteur

Santé

Industrie

Drug Manufacturers - Specialty & Generic

Pays

Japon

Siège

4-6-10 Koishikawa, 112-8088, Tokyo

Salariés

10 543

Cotation

4523 · TSE

Indices

Nikkei 225

Devise

JPY

ISIN

JP3160400002

Site web

eisai.co.jp